{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:56:27Z","timestamp":1773802587454,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diseases and toxins may lead to death of active liver tissue, resulting in a loss of total clearance capacity at the whole-body level. However, it remains difficult to study, whether the loss of metabolizing tissue is sufficient to explain loss of metabolic capacity of the liver or whether the surviving tissue undergoes an adaptive response to compensate the loss. To understand the cellular impact of toxic liver damage in an<jats:italic>in vivo<\/jats:italic>situation, we here used physiologically-based pharmacokinetic modelling to investigate pharmacokinetics of a specifically designed drug cocktail at three different sampling sites of the body in healthy mice and mice treated with carbon tetrachloride (CCl<jats:sub>4<\/jats:sub>). Liver zonation was explicitly quantified in the models through immunostaining of cytochrome P450s enzymes. Comparative analyses between the simulated decrease in clearance capacity and the experimentally measured loss in tissue volume indicated that CCl<jats:sub>4<\/jats:sub>-induced impairment of metabolic functions goes beyond the mere loss of metabolically active tissue. The here established integrative modelling strategy hence provides mechanistic insights into functional consequences of toxic liver damage in an<jats:italic>in vivo<\/jats:italic>situation, which would not have been accessible by conventional methods.<\/jats:p>","DOI":"10.1038\/s41598-017-04574-z","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T09:26:21Z","timestamp":1500369981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Physiologically-based modelling in mice suggests an aggravated loss of clearance capacity after toxic liver damage"],"prefix":"10.1038","volume":"7","author":[{"given":"Arne","family":"Schenk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ghallab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schuppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-9603","authenticated-orcid":false,"given":"Lars Ole","family":"Schwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Braeuning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Teutonico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.","family":"Hengstler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kuepfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"4574_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0163-7258(92)90055-5","volume":"53","author":"R Gebhardt","year":"1992","unstructured":"Gebhardt, R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacology & therapeutics 53, 275\u2013354 (1992).","journal-title":"Pharmacology & therapeutics"},{"key":"4574_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0306-3623(96)00183-8","volume":"28","author":"KO Lindros","year":"1997","unstructured":"Lindros, K. O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. General Pharmacology: The Vascular System 28, 191\u2013196 (1997).","journal-title":"General Pharmacology: The Vascular System"},{"key":"4574_CR3","doi-asserted-by":"crossref","unstructured":"Thurman, R. G., Kauffman, F. C. & Baron, J. In Regulation of hepatic metabolism 321\u2013382 (Springer, 1986).","DOI":"10.1007\/978-1-4684-5041-5_13"},{"key":"4574_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/713611034","volume":"33","author":"LW Weber","year":"2003","unstructured":"Weber, L. W., Boll, M. & Stampfl, A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Critical reviews in toxicology 33, 105\u2013136 (2003).","journal-title":"Critical reviews in toxicology"},{"key":"4574_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.27136","volume":"60","author":"F Schliess","year":"2014","unstructured":"Schliess, F. et al. Integrated metabolic spatial\u2010temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology 60, 2040\u20132051 (2014).","journal-title":"Hepatology"},{"key":"4574_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer, L. et al. Applied Concepts in PBPK Modeling: How to Build a PBPK\/PD Model. CPT Pharmacometrics Syst Pharmacol 5, 516\u2013531, doi:10.1002\/psp4.12134 (2016).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4574_CR7","first-page":"1","volume":"3","author":"L Kuepfer","year":"2014","unstructured":"Kuepfer, L., Kerb, R. & Henney, A. Clinical translation in the virtual liver network. CPT: pharmacometrics & systems pharmacology 3, 1\u20134 (2014).","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"4574_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jps.24214","volume":"104","author":"C Thiel","year":"2015","unstructured":"Thiel, C. et al. A Systematic Evaluation of the Use of Physiologically Based Pharmacokinetic Modeling for Cross\u2010Species Extrapolation. Journal of pharmaceutical sciences 104, 191\u2013206 (2015).","journal-title":"Journal of pharmaceutical sciences"},{"key":"4574_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharmaceutical research 10, 1093\u20131095 (1993).","journal-title":"Pharmaceutical research"},{"key":"4574_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2174\/138920009788898037","volume":"10","author":"P Li","year":"2009","unstructured":"Li, P., Wang, G.-J., Robertson, T. A. & Roberts, M. S. Liver transporters in hepatic drug disposition: an update. Current drug metabolism 10, 482\u2013498 (2009).","journal-title":"Current drug metabolism"},{"key":"4574_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1208\/s12248-009-9088-1","volume":"11","author":"HM Jones","year":"2009","unstructured":"Jones, H. M., Gardner, I. B. & Watson, K. J. Modelling and PBPK simulation in drug discovery. The AAPS journal 11, 155\u2013166 (2009).","journal-title":"The AAPS journal"},{"key":"4574_CR12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1124\/dmd.111.043174","volume":"40","author":"M Meyer","year":"2012","unstructured":"Meyer, M., Schneckener, S., Ludewig, B., Kuepfer, L. & Lippert, J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition 40, 892\u2013901 (2012).","journal-title":"Drug Metabolism and Disposition"},{"key":"4574_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00008571-199608000-00002","volume":"6","author":"JT Buters","year":"1996","unstructured":"Buters, J. T. et al. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics and Genomics 6, 291\u2013296 (1996).","journal-title":"Pharmacogenetics and Genomics"},{"key":"4574_CR14","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/S0006-2952(02)01019-5","volume":"63","author":"A Labedzki","year":"2002","unstructured":"Labedzki, A., Buters, J., Jabrane, W. & Fuhr, U. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Biochemical pharmacology 63, 2159\u20132167 (2002).","journal-title":"Biochemical pharmacology"},{"key":"4574_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3109\/03602538409029964","volume":"15","author":"M Bonati","year":"1983","unstructured":"Bonati, M., Latini, R., Tognoni, G., Young, J. & Garattini, S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug metabolism reviews 15, 1355\u20131383 (1983).","journal-title":"Drug metabolism reviews"},{"key":"4574_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/dmd.31.5.548","volume":"31","author":"CP Granvil","year":"2003","unstructured":"Granvil, C. P. et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug metabolism and disposition 31, 548\u2013558 (2003).","journal-title":"Drug metabolism and disposition"},{"key":"4574_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/dmd.107.017962","volume":"36","author":"B Zhu","year":"2008","unstructured":"Zhu, B. et al. Characterization of 1\u2032-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metabolism and Disposition 36, 331\u2013338 (2008).","journal-title":"Drug Metabolism and Disposition"},{"key":"4574_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","volume":"34","author":"H Knauf","year":"1998","unstructured":"Knauf, H. & Mutschler, E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clinical pharmacokinetics 34, 1\u201324 (1998).","journal-title":"Clinical pharmacokinetics"},{"key":"4574_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/00498259009046884","volume":"20","author":"K Oguri","year":"1990","unstructured":"Oguri, K., Hanioka, N. & Yoshimura, H. Species differences in metabolism of codeine: urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 20, 683\u2013688 (1990).","journal-title":"Xenobiotica"},{"key":"4574_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1124\/dmd.105.008870","volume":"34","author":"A-M Yu","year":"2006","unstructured":"Yu, A.-M. & Haining, R. L. Expression, purification, and characterization of mouse CYP2d22. Drug metabolism and disposition 34, 1167\u20131174 (2006).","journal-title":"Drug metabolism and disposition"},{"key":"4574_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5414\/CPP39061","volume":"39","author":"M Krueger","year":"2001","unstructured":"Krueger, M. et al. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. International journal of clinical pharmacology and therapeutics 39, 61\u201366 (2001).","journal-title":"International journal of clinical pharmacology and therapeutics"},{"key":"4574_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/(SICI)1096-9888(199612)31:12<1371::AID-JMS433>3.0.CO;2-4","volume":"31","author":"H Schupke","year":"1996","unstructured":"Schupke, H., Hempel, R., Eckardt, R. & Kronbach, T. Identification of Talinolol Metabolites in Urine of Man, Dog, Rat and Mouse after Oral Administration by High\u2010Performance Liquid Chromatography\u2013Thermospray Tandem Mass Spectrometry. Journal of mass spectrometry 31, 1371\u20131381 (1996).","journal-title":"Journal of mass spectrometry"},{"key":"4574_CR23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0090-9556(25)08889-0","volume":"19","author":"DW Everett","year":"1991","unstructured":"Everett, D. W. et al. Biotransformation of pravastatin sodium in humans. Drug metabolism and disposition 19, 740\u2013748 (1991).","journal-title":"Drug metabolism and disposition"},{"key":"4574_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","volume":"39","author":"T Hatanaka","year":"2000","unstructured":"Hatanaka, T. Clinical pharmacokinetics of pravastatin. Clinical pharmacokinetics 39, 397\u2013412 (2000).","journal-title":"Clinical pharmacokinetics"},{"key":"4574_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255\u2013268 (1989).","journal-title":"Biometrics"},{"key":"4574_CR26","doi-asserted-by":"publisher","first-page":"e1003499","DOI":"10.1371\/journal.pcbi.1003499","volume":"10","author":"LO Schwen","year":"2014","unstructured":"Schwen, L. O. et al. Spatio-temporal simulation of first pass drug perfusion in the liver. PLoS computational biology 10, e1003499, doi:10.1371\/journal.pcbi.1003499 (2014).","journal-title":"PLoS computational biology"},{"key":"4574_CR27","doi-asserted-by":"publisher","first-page":"25187","DOI":"10.1038\/srep25187","volume":"6","author":"CC Bell","year":"2016","unstructured":"Bell, C. C. et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific reports 6, 25187, doi:10.1038\/srep25187 (2016).","journal-title":"Scientific reports"},{"key":"4574_CR28","doi-asserted-by":"publisher","first-page":"26868","DOI":"10.1038\/srep26868","volume":"6","author":"WJ McCarty","year":"2016","unstructured":"McCarty, W. J., Usta, O. B. & Yarmush, M. L. A Microfabricated Platform for Generating Physiologically-Relevant Hepatocyte Zonation. Scientific reports 6, 26868, doi:10.1038\/srep26868 (2016).","journal-title":"Scientific reports"},{"key":"4574_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2015.11.018","volume":"64","author":"A Ghallab","year":"2016","unstructured":"Ghallab, A. et al. Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. Journal of hepatology 64, 860\u2013871, doi:10.1016\/j.jhep.2015.11.018 (2016).","journal-title":"Journal of hepatology"},{"key":"4574_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/dmd.104.001222","volume":"33","author":"TS Maurer","year":"2005","unstructured":"Maurer, T. S., DeBartolo, D. B., Tess, D. A. & Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug metabolism and disposition 33, 175\u2013181 (2005).","journal-title":"Drug metabolism and disposition"},{"key":"4574_CR31","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1124\/dmd.108.020479","volume":"36","author":"RS Obach","year":"2008","unstructured":"Obach, R. S., Lombardo, F. & Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metabolism and Disposition 36, 1385\u20131405 (2008).","journal-title":"Drug Metabolism and Disposition"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04574-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04574-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04574-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:29:28Z","timestamp":1750775368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04574-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["4574"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-04574-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"28 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An.S., D.T. and L.K. are employees of Bayer AG, the company developing the PBPK modelling tools PK-Sim and MoBi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6224"}}